A new therapeutic target for childhood medulloblastoma
Professor Stuart Pitson
Improving children’s mental health and the impact of developmental disorders.
University of South Australia
Medulloblastoma is the most common brain cancer in children. While the current treatment of surgery, radiotherapy and chemotherapy can increase survival rates for some children with medulloblastoma, this treatment often causes severe side effects and life-long disabilities. Thus, new therapies for medulloblastoma are desperately needed. We have identified a new therapeutic target for medulloblastoma, supported by compelling experimental data, and have developed new inhibitors of this target that offer promise for development as a medulloblastoma therapy. This proposal outlines the pre-clinical evaluation of this approach with successful outcomes likely to lead to future clinical trials for the treatment of medulloblastoma.